Hutchinson-Gilford Syndrome Completed Phase 2 Trials for Lonafarnib (DB06448)

IndicationStatusPhase
DBCOND0036510 (Hutchinson-Gilford Syndrome)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00425607Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaTreatment
NCT00879034A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaTreatment